메뉴 건너뛰기




Volumn 114, Issue 1, 2014, Pages 70-77

Recent advances in the search for novel 5-lipoxygenase inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

LICOFELONE; LIPOXYGENASE INHIBITOR;

EID: 84890802231     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12114     Document Type: Review
Times cited : (120)

References (53)
  • 1
    • 0023076232 scopus 로고
    • Human leukocyte 5-lipoxygenase: an enzyme possessing dual enzymatic activities and a multicomponent regulatory system
    • Samuelsson B, Rouzer CA, Matsumoto T. Human leukocyte 5-lipoxygenase: an enzyme possessing dual enzymatic activities and a multicomponent regulatory system. Adv Prostaglandin Thromboxane Leukot Res 1987;17A:1-11.
    • (1987) Adv Prostaglandin Thromboxane Leukot Res , vol.17 A , pp. 1-11
    • Samuelsson, B.1    Rouzer, C.A.2    Matsumoto, T.3
  • 2
    • 46749115524 scopus 로고    scopus 로고
    • Leukotrienes, antileukotrienes and asthma
    • Montuschi P. Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem 2008;8:647-56.
    • (2008) Mini Rev Med Chem , vol.8 , pp. 647-656
    • Montuschi, P.1
  • 3
    • 33750102847 scopus 로고    scopus 로고
    • Therapeutic options for 5-lipoxygenase inhibitors
    • Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 2006;112:701-18.
    • (2006) Pharmacol Ther , vol.112 , pp. 701-718
    • Werz, O.1    Steinhilber, D.2
  • 4
    • 67649861052 scopus 로고    scopus 로고
    • Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
    • Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009;41:783-92.
    • (2009) Nat Genet , vol.41 , pp. 783-792
    • Chen, Y.1    Hu, Y.2    Zhang, H.3    Peng, C.4    Li, S.5
  • 6
  • 8
    • 0030835266 scopus 로고    scopus 로고
    • 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice
    • Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997;272:L1053-8.
    • (1997) Am J Physiol , vol.272
    • Irvin, C.G.1    Tu, Y.P.2    Sheller, J.R.3    Funk, C.D.4
  • 9
    • 17444440118 scopus 로고    scopus 로고
    • Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice
    • Griffiths RJ, Smith MA, Roach ML, Stock JL, Stam EJ, Milici AJ et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J Exp Med 1997;185:1123-9.
    • (1997) J Exp Med , vol.185 , pp. 1123-1129
    • Griffiths, R.J.1    Smith, M.A.2    Roach, M.L.3    Stock, J.L.4    Stam, E.J.5    Milici, A.J.6
  • 10
    • 0033523672 scopus 로고    scopus 로고
    • "Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening
    • Schneider G, Neidhart W, Giller T, Schmid G. "Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed Engl 1999;38:2894-6.
    • (1999) Angew Chem Int Ed Engl , vol.38 , pp. 2894-2896
    • Schneider, G.1    Neidhart, W.2    Giller, T.3    Schmid, G.4
  • 11
    • 66149130697 scopus 로고    scopus 로고
    • 2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton
    • Joshi EM, Heasley BH, Macdonald TL. 2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton. Xenobiotica 2009;39:197-204.
    • (2009) Xenobiotica , vol.39 , pp. 197-204
    • Joshi, E.M.1    Heasley, B.H.2    Macdonald, T.L.3
  • 13
    • 33947369029 scopus 로고    scopus 로고
    • Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease
    • Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663-76.
    • (2007) Int J Clin Pract , vol.61 , pp. 663-676
    • Berger, W.1    De Chandt, M.T.2    Cairns, C.B.3
  • 14
    • 84890807582 scopus 로고    scopus 로고
    • http://crtx.com/docs/zyflo_cr_pi.pdf/June 2013
  • 15
    • 77953642757 scopus 로고    scopus 로고
    • Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome
    • Tardif JC, L'Allier PL, Ibrahim R, Gregoire JC, Nozza A, Cossette M et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010;3:298-307.
    • (2010) Circ Cardiovasc Imaging , vol.3 , pp. 298-307
    • Tardif, J.C.1    L'Allier, P.L.2    Ibrahim, R.3    Gregoire, J.C.4    Nozza, A.5    Cossette, M.6
  • 16
    • 84890789835 scopus 로고    scopus 로고
    • BIOL-B380 Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December, American Chemical Society, Washington, DC, 2010.
    • Taub R. Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with established atherosclerosis. Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December, 2010, American Chemical Society, Washington, DC, 2010;BIOL-380.
    • (2010) Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with established atherosclerosis
    • Taub, R.1
  • 19
    • 79151482943 scopus 로고    scopus 로고
    • MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease
    • Bernstein JA, Liu N, Knorr BA, Smugar SS, Hanley WD, Reiss TF et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir Med 2011;105:392-401.
    • (2011) Respir Med , vol.105 , pp. 392-401
    • Bernstein, J.A.1    Liu, N.2    Knorr, B.A.3    Smugar, S.S.4    Hanley, W.D.5    Reiss, T.F.6
  • 20
    • 79955026356 scopus 로고    scopus 로고
    • Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor
    • Maciolek CM, Ma B, Menzel K, Laliberte S, Bateman K, Krolikowski P et al. Novel cytochrome P450-mediated ring opening of the 1, 3, 4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2011;39:763-70.
    • (2011) Drug Metab Dispos , vol.39 , pp. 763-770
    • Maciolek, C.M.1    Ma, B.2    Menzel, K.3    Laliberte, S.4    Bateman, K.5    Krolikowski, P.6
  • 21
    • 84890803308 scopus 로고    scopus 로고
    • BIOL-B382 Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December, American Chemical Society, Washington, DC, 2010.
    • Ducharme Y. Discovery and development of potent 5-lipoxygenase inhibitors. Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December 2010, American Chemical Society, Washington, DC, 2010;BIOL-382.
    • (2010) Discovery and development of potent 5-lipoxygenase inhibitors
    • Ducharme, Y.1
  • 22
    • 77953771000 scopus 로고    scopus 로고
    • Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain
    • Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L et al. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther 2010;334:294-301.
    • (2010) J Pharmacol Exp Ther , vol.334 , pp. 294-301
    • Masferrer, J.L.1    Zweifel, B.S.2    Hardy, M.3    Anderson, G.D.4    Dufield, D.5    Cortes-Burgos, L.6
  • 24
    • 77953751021 scopus 로고    scopus 로고
    • In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase
    • Matthew Hutzler J, Linder CD, Melton RJ, Vincent J, Daniels JS. In vitro-in vivo correlation and translation to the clinical outcome for CJ-13, 610, a novel inhibitor of 5-lipoxygenase. Drug Metab Dispos 2010;38:1113-21.
    • (2010) Drug Metab Dispos , vol.38 , pp. 1113-1121
    • Matthew Hutzler, J.1    Linder, C.D.2    Melton, R.J.3    Vincent, J.4    Daniels, J.S.5
  • 25
    • 69949138207 scopus 로고    scopus 로고
    • The use of gastrointestinal intubation studies for controlled release development
    • Sutton SC. The use of gastrointestinal intubation studies for controlled release development. Br J Clin Pharmacol 2009;68:342-54.
    • (2009) Br J Clin Pharmacol , vol.68 , pp. 342-354
    • Sutton, S.C.1
  • 26
    • 84890785914 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/April 2013
    • (2013)
  • 27
    • 34848921503 scopus 로고    scopus 로고
    • A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation
    • Burnett BP, Jia Q, Zhao Y, Levy RM. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 2007;10:442-51.
    • (2007) J Med Food , vol.10 , pp. 442-451
    • Burnett, B.P.1    Jia, Q.2    Zhao, Y.3    Levy, R.M.4
  • 28
    • 79952116933 scopus 로고    scopus 로고
    • Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee
    • Levy RM, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kantemirova R et al. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv Ther 2010;27:731-42.
    • (2010) Adv Ther , vol.27 , pp. 731-742
    • Levy, R.M.1    Khokhlov, A.2    Kopenkin, S.3    Bart, B.4    Ermolova, T.5    Kantemirova, R.6
  • 29
    • 84862734518 scopus 로고    scopus 로고
    • Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series
    • W297-300.
    • Chalasani N, Vuppalanchi R, Navarro V, Fontana R, Bonkovsky H, Barnhart H et al. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med 2012;156:857-60, W297-300.
    • (2012) Ann Intern Med , vol.156 , pp. 857-860
    • Chalasani, N.1    Vuppalanchi, R.2    Navarro, V.3    Fontana, R.4    Bonkovsky, H.5    Barnhart, H.6
  • 30
    • 76149142698 scopus 로고    scopus 로고
    • Zileuton, a new efficient and safe systemic anti-acne drug
    • Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinology 2009;1:188-92.
    • (2009) Dermatoendocrinology , vol.1 , pp. 188-192
    • Zouboulis, C.C.1
  • 31
    • 0028289770 scopus 로고
    • (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase
    • Laufer SA, Augustin J, Dannhardt G, Kiefer W. (6, 7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 1994;37:1894-7.
    • (1994) J Med Chem , vol.37 , pp. 1894-1897
    • Laufer, S.A.1    Augustin, J.2    Dannhardt, G.3    Kiefer, W.4
  • 32
    • 0042388365 scopus 로고    scopus 로고
    • Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin
    • Fiorucci S, Distrutti E, Mencarelli A, Morelli A, Laufor SA, Cirino G et al. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol 2003;139:1351-9.
    • (2003) Br J Pharmacol , vol.139 , pp. 1351-1359
    • Fiorucci, S.1    Distrutti, E.2    Mencarelli, A.3    Morelli, A.4    Laufor, S.A.5    Cirino, G.6
  • 33
    • 19544368809 scopus 로고    scopus 로고
    • The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway
    • Boileau C, Pelletier JP, Tardif G, Fahmi H, Laufer S, Lavigne M et al. The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann Rheum Dis 2005;64:891-8.
    • (2005) Ann Rheum Dis , vol.64 , pp. 891-898
    • Boileau, C.1    Pelletier, J.P.2    Tardif, G.3    Fahmi, H.4    Laufer, S.5    Lavigne, M.6
  • 34
    • 35348914335 scopus 로고    scopus 로고
    • The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products
    • Fischer L, Hornig M, Pergola C, Meindl N, Franke L, Tanrikulu Y et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 2007;152:471-80.
    • (2007) Br J Pharmacol , vol.152 , pp. 471-480
    • Fischer, L.1    Hornig, M.2    Pergola, C.3    Meindl, N.4    Franke, L.5    Tanrikulu, Y.6
  • 35
    • 52649119793 scopus 로고    scopus 로고
    • Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1
    • Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S, Albrecht W et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008;326:975-82.
    • (2008) J Pharmacol Exp Ther , vol.326 , pp. 975-982
    • Koeberle, A.1    Siemoneit, U.2    Buhring, U.3    Northoff, H.4    Laufer, S.5    Albrecht, W.6
  • 36
    • 1242342177 scopus 로고    scopus 로고
    • Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis
    • Alvaro-Gracia JM. Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford) 2004;43(Suppl. 1):i21-5.
    • (2004) Rheumatology (Oxford) , vol.43 , Issue.SUPPL. 1
    • Alvaro-Gracia, J.M.1
  • 37
    • 44949130852 scopus 로고    scopus 로고
    • Licofelone: the answer to unmet needs in osteoarthritis therapy?
    • Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep 2008;10:43-8.
    • (2008) Curr Rheumatol Rep , vol.10 , pp. 43-48
    • Kulkarni, S.K.1    Singh, V.P.2
  • 38
    • 82555168047 scopus 로고    scopus 로고
    • 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-y lmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor
    • Stock NS, Bain G, Zunic J, Li Y, Ziff J, Roppe J et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-y lmethoxy)-1H-indol-2-yl]-2, 2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J Med Chem 2011;54:8013-29.
    • (2011) J Med Chem , vol.54 , pp. 8013-8029
    • Stock, N.S.1    Bain, G.2    Zunic, J.3    Li, Y.4    Ziff, J.5    Roppe, J.6
  • 39
    • 77949875056 scopus 로고    scopus 로고
    • Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)
    • Bain G, King CD, Rewolinski M, Schaab K, Santini AM, Shapiro D et al. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clin Pharmacol Ther 2010;87:437-44.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 437-444
    • Bain, G.1    King, C.D.2    Rewolinski, M.3    Schaab, K.4    Santini, A.M.5    Shapiro, D.6
  • 40
    • 0027492042 scopus 로고
    • Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds
    • Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Muller-Peddinghaus R. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Biochem Pharmacol 1993;45:101-11.
    • (1993) Biochem Pharmacol , vol.45 , pp. 101-111
    • Hatzelmann, A.1    Fruchtmann, R.2    Mohrs, K.H.3    Raddatz, S.4    Muller-Peddinghaus, R.5
  • 41
    • 18244403498 scopus 로고    scopus 로고
    • Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial
    • Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005;293:2245-56.
    • (2005) JAMA , vol.293 , pp. 2245-2256
    • Hakonarson, H.1    Thorvaldsson, S.2    Helgadottir, A.3    Gudbjartsson, D.4    Zink, F.5    Andresdottir, M.6
  • 43
    • 84863353889 scopus 로고    scopus 로고
    • Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors
    • Wu Y, He C, Gao Y, He S, Liu Y, Lai L. Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors. J Med Chem 2012;55:2597-605.
    • (2012) J Med Chem , vol.55 , pp. 2597-2605
    • Wu, Y.1    He, C.2    Gao, Y.3    He, S.4    Liu, Y.5    Lai, L.6
  • 45
    • 48749125396 scopus 로고    scopus 로고
    • Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening
    • Tanrikulu Y, Schneider G. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat Rev Drug Discov 2008;7:667-77.
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 667-677
    • Tanrikulu, Y.1    Schneider, G.2
  • 46
    • 34250164182 scopus 로고    scopus 로고
    • Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening
    • Franke L, Schwarz O, Muller-Kuhrt L, Hoernig C, Fischer L, George S et al. Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem 2007;50:2640-6.
    • (2007) J Med Chem , vol.50 , pp. 2640-2646
    • Franke, L.1    Schwarz, O.2    Muller-Kuhrt, L.3    Hoernig, C.4    Fischer, L.5    George, S.6
  • 51
    • 84870236442 scopus 로고    scopus 로고
    • A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma
    • Evans RL, Nials AT, Knowles RG, Kidd EJ, Ford WR, Broadley KJ. A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma. Pulm Pharmacol Ther 2012;25:453-64.
    • (2012) Pulm Pharmacol Ther , vol.25 , pp. 453-464
    • Evans, R.L.1    Nials, A.T.2    Knowles, R.G.3    Kidd, E.J.4    Ford, W.R.5    Broadley, K.J.6
  • 52
    • 84872964202 scopus 로고    scopus 로고
    • Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants
    • Hofheinz K, Kakularam KR, Adel S, Anton M, Polymarasetty A, Reddanna P et al. Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants. Arch Biochem Biophys 2012;530:40-7.
    • (2012) Arch Biochem Biophys , vol.530 , pp. 40-47
    • Hofheinz, K.1    Kakularam, K.R.2    Adel, S.3    Anton, M.4    Polymarasetty, A.5    Reddanna, P.6
  • 53
    • 84877948851 scopus 로고    scopus 로고
    • Rationally designed multitarget agents against inflammation and pain
    • Hwang SH, Wecksler AT, Wagner K, Hammock BD. Rationally designed multitarget agents against inflammation and pain. Curr Med Chem 2013;20:1783-99.
    • (2013) Curr Med Chem , vol.20 , pp. 1783-1799
    • Hwang, S.H.1    Wecksler, A.T.2    Wagner, K.3    Hammock, B.D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.